ひとことで言うと
Lilly is one of the world's largest pharmaceutical companies. It entered gene editing by buying Verve Therapeutics in 2025 for around a billion dollars, acquiring a programme designed to lower cholesterol permanently with a single treatment — a signal that large pharmaceutical companies now see in vivo editing as a serious commercial proposition rather than a science project.
Eli Lilly and Company acquired Verve Therapeutics in 2025 for approximately $1 billion plus contingent value rights, adding in vivo base editing for cardiovascular disease to a portfolio spanning metabolic, oncology and neuroscience medicines. The transaction is among the clearest indications of large-pharma conviction in the modality.
Sources
- Eli Lilly and Company · 2025
Lilly to acquire Verve Therapeutics ↗
投資アドバイスではありません
このプロフィールは、公開情報をもとに作成した教育目的の情報です。いかなる有価証券の購入・売却・保有を推奨するものでも、企業の見通しに関する見解を示すものでもありません。バイオテクノロジーは投機性が高く、ほとんどの臨床プログラムは失敗に終わります。
免責事項の全文 →